NIDA Clinical Trials Network: New York Node

NIDA 临床试验网络：纽约节点

• 批准号: 10438312
• 负责人: Edward V. Nunes
• 金额: $ 15.74万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-01-10 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10438312
• 关键词: Academia; Accident and Emergency department; Address; Adoption; Advocacy; Affect; Alaska Native; Alcohols; American Indians; Ancillary Study; Area; Behavior Therapy; Behavioral; Buprenorphine; Caring; Cities; Clinic; Clinical; Clinical Management; Clinical Research; Clinical Trials; Clinical Trials Network; Communities; Criminal Justice; Data; Data Analytics; Data Science; Data Set; Effectiveness; Electronic Health Record; Elements; Ethnic Origin; Evaluation; Event; Evidence based intervention; Female; Funding; Future; Gender; Generations; Goals; Health; Health Personnel; Healthcare Systems; Heterogeneity; Hispanics; Individual; Infrastructure; Injections; Intervention; Latinx; Lead; Long Island; Mainstreaming; Measurement; Medical; Mental disorders; Meta-Analysis; Minority; Minority Groups; Modality; Modeling; Naltrexone; National Institute of Drug Abuse; New York; Nicotine; Opioid; Outcome; Participant; Patients; Pharmaceutical Preparations; Pharmacology; Pharmacotherapy; Policies; Policy Maker; Predictive Value; Prevention; Prevention trial; Primary Health Care; Provider; Psychostimulant dependence; Public Health; Race; Randomized; Research; Research Personnel; Schedule; Science; Scientist; Services; Substance Use Disorder; Surveys; Technology; Testing; Tobacco; Training; Translating; Treatment outcome; United States National Institutes of Health; Variant; Vision; Withdrawal; Woman; Work; addiction; base; black women; care providers; clinical research site; clinically significant; cost; data sharing; digital; health care settings; health economics; implementation facilitation; implementation science; improved; innovation; interest; male; medical specialties; metropolitan; nicotine use; novel; opioid epidemic; opioid use; opioid use disorder; pre-exposure prophylaxis; predictive modeling; racial and ethnic; sex; stimulant use disorder; success; treatment as usual; treatment program; treatment research; trial design; virtual; web site

The New York Node (NYN) of the NIDA CTN, led by John Rotrosen and Edward Nunes, represents the 2010 merger of the New York and Long Island Nodes, which had been part of the CTN since 2000 and 2001, respectively. This fourth competing renewal application builds on both a strong and successful infrastructure to manage clinical trials, and a track record of innovation and successful implementation of trials in mainstream healthcare settings where most SUD patients are seen. We contribute expertise in virtually all key CTN priorities outlined in RFA-DA-20-024, including: integration of SUD treatment and prevention in mainstream settings (primary care, emergency departments, criminal justice); leveraging the electronic health record to support improved and expanded care; developing medications and behavioral therapies; co-occurring medical and psychiatric disorders; women and minorities; digital and other technology-based interventions; data science including novel data analytic approaches; and implementation science, health economics, advocacy, and policy to sustain evidence-based interventions. In the new funding period, the NYN will lead or co-lead seven ambitious projects, all scheduled to begin in 2019 or 2020: CTN-0079-A1 Ancillary Study of the Adoption and Sustainability of ED-Initiated Buprenorphine; CTN-0082 Implementation Survey of PrEP and Opioid Use Related Services in STI Clinics and Community Based Organizations; CTN-0094 Individual Level Predictive Modeling of Opioid Use Disorder Treatment Outcome; CTN-0096 Culturally Centered MAT for OUD Implementation Facilitation for Primary Care and Addiction Treatment Programs Serving American Indian/Alaska Natives; CTN-0097 Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder; CTN-0100 Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy; and CTN-0101 Subthreshold Opioid Use Disorder Prevention (STOP) Trial. We will also continue to help develop new trials in CTN, including in the area of stimulant dependence, and to supply sites for CTN trials. To support this, we have built a network of collaborating researchers, providers, and policy makers from academia, community-based addiction treatment programs, large multifaceted healthcare systems, and NY City and State agencies, all in the nation’s largest and most diverse metropolitan area. We have established a track record of substantial contributions to the CTN, building on our work through deliberate, rigorous, and stepwise improvements. Our vision for the Network’s future includes work built around addressing gaps highlighted by the opioid treatment cascade, interventions for stimulant dependence, effective use of the CTN platform to enable a broad range of non-CTN studies, and a continued commitment to training a new generation of addictions clinical researchers. Further, we partner with implementation scientists, health economists, advocacy groups, and policy experts to maximize the sustainability of effective new interventions.

由John Rotrosen和Edward Nunes领导的NIDA CTN的纽约节点（NYN）代表2010年 自2000年和2001年以来一直是CTN的一部分，纽约和长岛节点的合并 分别。第四次竞争的续订应用程序都建立在强大而成功的基础设施上 管理临床试验，以及创新和成功实施主流试验的记录 大多数SUD患者的医疗保健环境。我们在几乎所有关键CTN上都有贡献专业知识 RFA-DA-20-024中概述的优先级，包括：SUD治疗和预防的整合 设置（初级保健，急诊部，刑事司法）；利用电子健康记录 支持改善和扩大护理；开发药物和行为疗法；同时出现的医疗 和精神疾病；妇女和少数民族；数字和其他基于技术的干预措施；数据 科学在内，包括新颖的数据分析方法；以及实施科学，卫生经济学，倡导， 以及维持基于证据的干预措施的政策。在新的资金期间，NYN将领导或共同领导 七个雄心勃勃的项目，原定于2019年或2020年开始：CTN-0079-A1采用辅助研究 和启发的丁丙诺啡的可持续性； CTN-0082 PREP和阿片类药物使用的实施调查 STI诊所和社区组织的相关服务； CTN-0094个人级别预测 阿片类药物使用障碍治疗结果的建模； CTN-0096以文化为中心的垫子 初级保健和成瘾治疗计划的实施便利，为美国的服务 印度/阿拉斯加本地人； CTN-0097超越戒断以开始使用纳曲酮（SWIFT）快速治疗： 提高注射纳曲酮对阿片类药物使用障碍的现实有效性； CTN-0100优化 阿片类药物使用障碍药物治疗的保留，持续时间和中断策略；和CTN-0101 亚阈值预防障碍（Stop）试验。我们还将继续帮助开发新的试验 CTN，包括在兴奋剂依赖性领域以及为CTN试验提供位点。 为了支持这一点，我们建立了一个由合作的研究人员，提供者和政策制定者的网络 学术界，基于社区的成瘾治疗计划，大型多面医疗保健系统和纽约 城市和州机构，都是美国最大，最多样化的大都市地区。我们已经建立了 对CTN的实质性贡献的记录，通过故意，严格和 逐步改进。我们对网络未来的愿景包括围绕解决空白的工作 由阿片类药物治疗级联突出显示，刺激依赖性的干预措施，有效地使用CTN 平台实现广泛的非CTN研究，并继续致力于培训新的研究 成瘾的产生临床研究人员。此外，我们与实施科学家合作，健康 经济学家，倡导团体和政策专家，以最大化有效的新干预措施的可持续性。